Cure My Disease

Don't miss your cure!

 Log in / Sign up

VR headset tracks eyes to unlock new diagnostic insights

NCT ID NCT07258212

Knowledge-focused Sponsor: machineMD AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gathers standard eye movement and pupil data from 200 healthy volunteers, children, and people with eye or brain conditions using a VR headset called neos™. The headset shows images and tracks where participants look, how their pupils react, and how their eyes move. The goal is to create a baseline to help doctors better diagnose neuro-ophthalmological disorders. No treatment is given—only data collection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The recruitment of healthy volunteers will take place at medical and non-medical sites through advertisement. The recruitment of neurological and ophthalmic patients will take place at medical sites through the Principal Investigator.

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Healthy Volunteers: * Age \> 3 * Informed consent by participant and/or legal representative documented per signature * Snellen visual acuity ≥ +0.1 LogMAR, with correction, on both eyes * Refractive error between -10 and +5 diopters, on both eyes Exclusion Criteria Healthy Volunteers: * Known ophthalmological, neurological or vestibular disease * Current medication/drugs that could potentially influence performance in ocular motor tasks and/or compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, or stimulants) * Stimulative medication (e.g. with Ritalin®) * Known substance abuse Inclusion Criteria Patients: * Age \> 3 * Informed consent by participant and/or legal representative, designated trusted person or next of kin, documented per signature * Refractive error between -10 and +5 diopters, on both eyes * Known ophthalmological or neurological disease Exclusion Criteria Patients: * Visual acuity in one or both eyes \< +1.3 LogMAR * Incapacity to understand and comply with the examination in the opinion of the investigator (e.g. due to very advanced dementia, with failure to comply with easy experimental instructions and tasks) * Known substance abuse

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuro-ophthalmology are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuro-ophthalmology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inselspital, Bern university hospital

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

  • Onovis Augenpraxis

    RECRUITING

    Bern, Canton of Bern, 3011, Switzerland

  • machineMD AG

    RECRUITING

    Bern, Canton of Bern, 3008, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.